Global Hormonal Contraceptive Market

Hormonal Contraceptive Market Size, Share, Growth Analysis, By Product (Oral Contraceptive Pills, Injectable Birth Control), By Hormones (Progestin Only Contraceptive, Combined Hormonal Contraceptive), By Age (15-24 Years, 25-34 Years), By End User, By Region - Industry Forecast 2026-2033

Report ID: SQMIG35I2132 | Region: Global | Published Date: December, 2025
Pages: 157 |Tables: 62 |Figures: 80

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Hormonal Contraceptive Market size was valued at USD 20.11 Billion in 2024 and is poised to grow from USD 20.95 Billion in 2025 to USD 29.12 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026–2033).

    The global hormonal contraceptive market is highly competitive, with several established players and a number of new entrants vying for market share. The key companies offer a range of hormonal contraceptive products, including birth control pills, patches, injections, vaginal rings, and intrauterine devices (IUDs). In addition to product offerings, companies in the market compete on factors such as pricing, distribution, marketing, and research and development. 'Bayer AG (Germany) ', 'Pfizer Inc. (USA) ', 'Merck & Co., Inc. (USA) ', 'Johnson & Johnson (USA) ', 'AbbVie Inc. (USA) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Mylan N.V. (USA) ', 'Viatris Inc. (USA) ', 'Organon & Co. (USA) ', 'Mithra Pharmaceuticals (Belgium) ', 'Agile Therapeutics, Inc. (USA) ', 'Mayne Pharma Group Limited (Australia) ', 'Afaxys, Inc. (USA) ', 'Pregna International Ltd. (India) ', 'Lupin Pharmaceuticals Inc. (India) ', 'Cipla Limited (India) ', 'Sun Pharmaceutical Industries Limited (India) ', 'Piramal Enterprises Limited (India)'

    One of the major drivers of the global hormonal contraceptive market is the increasing awareness and acceptance of contraception as a means of family planning. With rising population levels, particularly in developing countries, there is a growing need for effective birth control methods to help couples manage their family size and spacing. This has led to a significant increase in the adoption of hormonal contraceptives, as they are highly effective in preventing unintended pregnancies and offer a convenient and reversible method of birth control.

    Increasing Preference for Long-Acting Reversible Contraceptives (LARCs): One of the key trends in the global hormonal contraceptive market is the increasing popularity of LARCs such as intrauterine devices (IUDs) and subdermal implants. LARCs are highly effective in preventing unintended pregnancies and can last for several years, providing women with a convenient and hassle-free contraceptive option. As a result, there has been a growing demand for LARCs, particularly among younger women and those seeking a more reliable contraceptive method.

    North America is the largest market for hormonal contraceptives, driven by the high awareness and adoption of contraception in the region. There is a high level of awareness and adoption of hormonal contraceptives in North America, with a large percentage of women using some form of contraception. This is driven by factors such as education, access to healthcare, and cultural acceptance of contraception. There is a wide range of hormonal contraceptive options available in North America, including birth control pills, patches, injections, vaginal rings, and intrauterine devices (IUDs). This gives women a choice of options to suit their needs and preferences. The market in North America is regulated by strong regulatory bodies such as the FDA in the US, which ensures that products are safe and effective before they can be marketed to consumers. North America has one of the highest levels of healthcare spending in the world, which ensures that hormonal contraceptives are widely available and accessible to women.

    Related Reports

    Contraceptives Market
    Buy Now GET FREE SAMPLE
    Contraceptive Drugs Market
    Buy Now GET FREE SAMPLE
    Non-Hormonal Contraception Market
    Buy Now GET FREE SAMPLE
    U.S. Contraceptive Market
    Buy Now GET FREE SAMPLE
    Contraceptive Devices Market
    Buy Now GET FREE SAMPLE
    Fertility Supplements Market
    Buy Now GET FREE SAMPLE
    Infertility Treatment Market
    Buy Now GET FREE SAMPLE
    Automatic Pill Dispenser Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Hormonal Contraceptive Market

    Report ID: SQMIG35I2132

    $5,300
    BUY NOW